Ovid Therapeutics Secures $7M Royalty Deal, Accelerates Phase 1 Pipeline

Introduction to Ovid Therapeutics Inc.

Ovid Therapeutics Inc. (NASDAQ: OVID) is a New York–based biopharmaceutical company founded in 2014 and known in Korea as 오비드 테라엔틱스. The firm focuses on developing targeted small-molecule therapies for epilepsy and other neurological conditions characterized by neuronal hyperexcitability. As of August 13, 2025, Ovid’s share price stood at $0.7096—up 29.73% on a volume of 1,001,175 shares traded.

Corporate Structure and Experience

Headquartered in New York, Ovid employs between 11 and 50 people across research, clinical development, regulatory affairs, and corporate functions. Its leadership team has a collective experience from major biotech and pharmaceutical companies and has contributed to the development and commercialization of more than 25 neurological and rare-disease medicines. Key figures include CEO Dr. Jeremy M. Levin and Chief Regulatory Officer Manal Morsy, MD, PhD, MBA.

Biopharmaceuticals by Kelly Sikkema

Recent Developments and News

• June 25, 2025: Ovid entered into a definitive agreement with Immedica Pharma AB, selling future royalties on global ganaxolone sales outside China for $7 million in cash. This agreement provides funding to support ongoing operations without impacting the core pipeline.
• Q2 2025 Update (LinkedIn, July 2025):
  • OV329, a next-generation GABA aminotransferase inhibitor, is progressing with topline Phase 1 data expected in Q3 2025.
  • OV350, a first-in-class KCC2 direct activator, is projected to deliver first-in-human data before December 31, 2025.
  • OV4071, an oral KCC2 activator, is advancing toward Phase 1 trials in the first half of 2026.
• August 13, 2025: Filing of Form 10-Q covering Q2 2025 financials and operational highlights.

Financial and Strategic Analysis

As of Q2 2025, Ovid reported trailing twelve-month revenue of $0.55 million and a net loss of $24.34 million. Cash and cash equivalents total $43 million, while total debt represents 24.34% of equity. Valuation metrics from Yahoo Finance include a market capitalization of $38.9 million, a Price/Sales ratio of 70.9, and a Price/Book ratio of 0.66. Levered free cash flow was negative $27.6 million over the last twelve months. The sale of ganaxolone royalties provides $7 million in non-dilutive capital, extending the cash runway through key clinical milestones.

Market Position and Industry Context

Ovid operates in the sector of central nervous system disorders, targeting epilepsy and related conditions. The company aims to modulate GABA-mediated inhibition and KCC2 transporter activity to provide potential alternatives to established anticonvulsants such as vigabatrin. With a beta of 0.21, the stock exhibits lower volatility compared to the broader biotech sector. At a share price below $1 and a sub-$40 million market cap, Ovid is categorized as a micro-cap company within a competitive landscape of established and emerging neuroscience firms.

tl;dr

Ovid’s June 25, 2025, $7 million sale of ganaxolone royalties to Immedica Pharma provides non-dilutive funding. Phase 1 topline data for OV329 is expected in Q3 2025, first-in-human results for OV350 by December 31, 2025, and OV4071 trials to initiate in H1 2026. As of August 13, 2025, the stock trades at $0.7096 (+29.73%), with a cash position of $43 million supporting upcoming clinical developments.